Xenetic Biosciences, Inc.
(NASDAQ : XBIO)

( )
XBIO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.01%90.691.3%$857.92m
AMGNAmgen Inc.
0.89%188.341.2%$633.58m
GILDGilead Sciences, Inc.
1.84%67.590.9%$514.47m
BIIBBiogen Inc.
2.51%332.871.3%$435.40m
REGNRegeneron Pharmaceuticals, Inc.
2.17%423.972.6%$309.18m
ILMNIllumina, Inc.
2.51%299.823.5%$302.75m
VRTXVertex Pharmaceuticals Incorporated
1.27%188.071.9%$286.68m
ALXNAlexion Pharmaceuticals, Inc.
2.77%129.422.0%$247.61m
AAgilent Technologies, Inc.
1.64%78.281.6%$135.81m
INCYIncyte Corporation
0.88%84.152.5%$133.07m
ALNYAlnylam Pharmaceuticals, Inc
0.60%83.539.2%$82.59m
BLUEBluebird Bio, Inc.
2.04%137.0314.4%$74.39m
SGENSeattle Genetics, Inc.
4.24%71.486.6%$67.96m
NKTRNektar Therapeutics
-2.18%41.695.5%$65.74m
TECHBio-Techne Corporation
1.63%191.634.7%$48.41m

Company Profile

Xenetic Biosciences, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company was founded on August 9, 2011 and is headquartered in Lexington, MA.